Hospital readmission for heart failure, is there anything else?
DOI:
https://doi.org/10.32818/reccmi.a9n2a21Keywords:
heart failure, amyloidosis, scintigraphy, echocardiographyAbstract
A 78-year-old man with multiple comorbidities and recurrent cardiac decompensation despite optimized
treatment. Differential diagnosis of the possible causes of refractory dyspnea was performed, with a diagnosis of
interstitial lung disease and cardiac amyloidosis. The diagnostic complexity was discussed, highlighting cardiac
amyloidosis as an important and underdiagnosed factor. Finally, the need for a comprehensive evaluation in clinical
cases with recurrent/refractory symptoms was pointed out.
Downloads
Metrics
References
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Rev Esp Cardiol (Engl Ed). 2022; 75(6): 523. doi: https://doi.org/10.1016/j.rec.2022.05.005 (último acceso jul. 2024). DOI: https://doi.org/10.1016/j.rec.2022.05.005
Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagli¬flozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021; 385(16): 1451-1461. doi: https://doi.org/10.1056/NEJMoa2107038 (último acceso jul. 2024). DOI: https://doi.org/10.1056/NEJMoa2107038
Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, et al. Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation. 2015; 131(1): 34-42. doi: https://doi.org/10.1161/CIRCULATIO¬NAHA.114.013255 (último acceso jul. 2024). DOI: https://doi.org/10.1161/CIRCULATIONAHA.114.013255
Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. Lancet. 2003; 362(9386): 777-781. doi: https:// doi.org/10.1016/S0140-6736(03)14285-7 (último acceso jul. 2024). DOI: https://doi.org/10.1016/S0140-6736(03)14285-7
González-López E, López-Sainz Á, Garcia-Pavia P. Diagnosis and treatment of transthyretin cardiac amyloidosis. Progress and hope. Rev Esp Cardiol (Engl Ed). 2017; 70(11): 991-1004. doi: https://doi.org/10.1016/j.rec.2017.05.036 (último acceso jul. 2024). DOI: https://doi.org/10.1016/j.rec.2017.05.036
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Daniel de la Cueva-Genovés, Víctor Urbaneja-Zumaquero, Salvador Martín-Cortés
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Permite compartir, copiar y redistribuir el material en cualquier medio o formato, bajo los siguientes términos:
Reconocimiento: debe otorgar el crédito correspondiente, proporcionar un enlace a la licencia e indicar si se realizaron cambios. Puede hacerlo de cualquier manera razonable, pero no de ninguna manera que sugiera que el licenciante lo respalda a usted o su uso.
No comercial: no puede utilizar el material con fines comerciales.
No Derivados: si remezcla, transforma o construye sobre el material, no puede distribuir el material modificado.
Sin restricciones adicionales: no puede aplicar términos legales o medidas tecnológicas que restrinjan legalmente a otros de hacer cualquier cosa que permita la licencia.
